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WE have  investigated  the  serum  concentrations  of
interleukin-6  (IL-6)  and  two  IL-6  family  cytokines–
oncostatin M  (OSM)  and leukemia inhibitory factor
(LIF)–in 63 patients with B-cell chronic lymphocytic
leukemia (B-CLL)  and 17 healthy controls using the
enzyme-linked  immunosorbent  assay  (ELISA)
method.  Simultaneously,  we  measured  the  serum
levels of the soluble forms of two subunits of the IL-6
receptor  complex-ligand  binding  glycoprotein  80
(sIL-6R) and glycoprotein 130 (sgp130). The cytokines
and receptors were evaluated in 25 untreated patients
and  38  patients  treated  with  cladribine  (2-CdA),  as
well as in 17 healthy controls. We have correlated the
serum levels of these proteins with Rai’s clinical stage
of the disease, the response to 2-CdA treatment and
some hematological parameters.  We have also eval-
uated the correlation of the IL-6 serum level with the
concentration of OSM and IL-6 soluble receptors. IL-6
was measurable in 62/63 (98.4%), OSM in 20/25 (80%)
of untreated and 14/38 (37.8%) of the treated patients.
sIL-6R and sgp130 were detectable in all 63 patients
and LIF in none of the CLL patients. IL-6 serum level
in untreated patients was not significantly different
as compared to its concentration in the control group
(P>0.05). However, in the patients treated with 2-CdA
the IL-6 level was significantly lower (P<0.02), and the
lowest concentration was found in the patients with
complete remission (CR; median 1.4 pg/ml; P<0.02).
The concentration of sIL-6R was significantly higher
in untreated (median 61.8 ng/ml) and treated (median
50.1 ng/ml) CLL patients when compared to normal
persons (median 41.2 ng/ml; P=0.04; P<0.001, respec-
tively). There was no difference between the sIL-6R
levels  in  the  patients  with  CR  and  the  healthy
controls.  In  non-responders  sIL-6R  concentration
was  the  highest  and  similar  to  its  level  in  the
untreated  patients.  OSM  level  was  higher  in  the
untreated  patients  (median  1.8 pg/ml)  than  in  the
normal controls (median 0.0 pg/ml; P<0.001) and in
the  CR  patients  (median  0.0 pg/ml;  P<0.03).  The
serum  concentration  of  sgp130  was  similar  in  the
untreated  (median  480 pg/ml)  and  treated  (median
470 pg/ml) patients, as well as in the healthy persons
(median  420 pg/ml;  P>0.05).  We  have  found  sig-
nificant positive correlation between the levels of sIL-
6R  and  the  lymphocytes  count  in  CLL  patients
(r =0.423;  P<0.001).  In  addition,  sIL-6R  and  OSM
serum  concentrations  correlated  also  with  CLL  Rai
stage. In conclusion, the serum level of IL-6, OSM and
sIL-6R, but not LIF and sgp130, are useful indicators of
CLL activity.
Key words: Chronic lymphocytic leukemia, Interleukin-6,
Oncostatin  M,  Leukemia  inhibitory  factor,  Soluble  inter-
leukin-6 receptor, gp 130, 2-CdA
Introduction
B-cell chronic lymphocytic leukemia (CLL) is the most
common leukemia in the Western world, characterized
by  the  clonal  proliferation  and  accumulation  of  B
lymphocytes.1,2These leukemic lymphocytes are char-
acterized by the expression of CD5 marker and low
density monoclonal membrane immunoglobulin (Ig).
Interleukin  2  (IL-2)  and  its  receptors  have  been
shown  to  play  a  central  role  in  the  mechanism
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ever, leukemic cells in this disorder have also been
observed to express several other cytokine receptors,
including  tumor  necrosis  factors  (TNF),5 colony
stimulating  factors  (CSF)3 and  interleukin-10
receptors.6
On the other hand, the leukemic cells in B-CLL can
themselves express and secrete some cytokines includ-
ing proinflammatory cytokines, such as TNFa 7,8 and
interleukin-6  (IL-6).7,9 IL-6  is  of  special  interest  in
B-CLL, because this cytokine acts as a B-cell stimulatory
factor (BSF-II), mediates B-cell differentiation and can
stimulate the growth of B-cell lymphoid malignancies
such as myeloma.10 In contrast, it has been proven that
IL-6 is also able to inhibit TNF-a induced proliferation
of B-cells from CLL patients.11,12
IL-6 is a member of a family of cytokines which also
includes leukemia inhibitory factor (LIF), oncostatin
M  (OSM),  ciliary  neurotrophic  factor  (CNTF)  and
interleukin  11  (IL-11).13,14 These  cytokines  are  a
group of evolutionary related proteins characterized
by a common tertiary  framework with a distinctive
four helix bundle topology.15,16
IL-6 related cytokines have also a gp130 receptor
component involved in the signal transduction across
the  cell  membrane,  which  explains  the  functional
pleiotropy and redundancy of IL-6 type cytokines.16 A
consequence could be the involvement of these four
cytokines,  in  a  similar  way  to  IL-6,  in  numerous
diseases including cancer, infections and autoimmune
diseases.13
The cellular IL-6 receptor complex consists of two
different proteins [an 80-kDa ligand binding glycopro-
tein  (IL-6R) and gp 130] and is involved in  cellular
signal transduction.17,18 These two subunits of the IL-
6R complex are proteolytically cleaved and released
from the cell as soluble receptor proteins.19,20 Soluble
forms of the IL-6R (sIL-6R) and gp130 (sgp130) have
been found in different body fluids in patients with
various inflammatory and neoplastic diseases.21,22
In the present study we have measured the serum
concentration of IL-6, LIF, OSM, as well as sIL-6R and
sgp130, in patients with active B-CLL and in patients
with  cladribine  (2-chlorodeoxyadenosine;  2-CdA)
induced  remission.  We  have  correlated  the  serum
levels  of  these  proteins  with  the  clinical  stage  of
disease according to Rai’s staging system, and some
hematological parameters. We have also evaluated the
correlation  between  the  serum  levels  of  IL-6  with
both OSM and IL-6 soluble receptors.
Patients and methods
Patients
The study comprised 63 patients (31 females and 32
males). Their mean age was 62.4 years (range 41–81
years). The characteristics of the patients are shown
T. Robak et al.
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Table 1. Clinical and laboratory characteristics of the patients with CLL
Patients’ characteristics Untreated
patients
Patients treated
with 2-CdA
Total
Total 25 38 63
Age (mean ± SD) 62.0±8.9 62.9±9.7 62.6±9.23
Range 47–81 41–81 41–81
Sex
Male 12 (48%) 20 (52.6%) 32 (50.8%)
Female 13 (52%) 18 (47.4%) 31 (49.2%)
Rai stage during analysis
0 3 (12%) 6 (15.8%) 9 (14.3%)
1&2 16 (64%) 11 (28.9%) 27 (42.9%)
3&4 6 (24%) 14 (36.8%) 20 (31.7%)
Patients in CR – 7 (18.5%) 7 (11.1%)
Patients without residual disease – 4 (10.5%) 4 (6.3%)
Hb concentration (g/dl)
Mean ± SD 12.3±2.0 12.4±2.1 12.4±2.1
Range 8.3–16.2 7.0–16.5 7.0–16.5
White blood cells (´ 10
9/l)
Mean ± SD 95.6±72.6 25.9±39.8 51.5±63.3
Range 20.09–310.0 1.74–210.0 1.74–310.0
Lymphocytes (10
9/l)
Mean ± SD 79.8±56.9 21.8±37.8 42.9±53.1
Range 13.26–283.2 0.12–199.5 0.1–283.1
Platelets (109/l)
Mean ± SD 159.7±53.2 121.9±43.1 135.3±50.9
Range 30.0–272.0 26.0–208.0 26.0–272.0in Table 1. All the patients fulfilled the National Cancer
Institute sponsored Working Group diagnostic criteria
for CLL.23 At diagnosis they had peripheral lymphocy-
tosis  greater  than  103 109/l  and  more  than  30%
lymphocytes in normal to hypercellular bone marrow.
Immunologically  all  the  patients  were  CD5,  CD19,
CD20 and CD23 positive and showed monoclonality
for  light  chain  immunoglobulin  membrane  surface
receptors.  Twenty-five  patients  were  previously
untreated  and  38  had been  previously treated with
2-CdA,  with  or  without  prednisone. The  treatment
method  has  been  described  elsewhere.24 However,
none of the patients had been treated for at least 4
weeks before the measurement of cytokines.
The clinical stage of the disease according to the
Rai’s  classification25 was  determined at  the  time  of
the blood sample collection for cytokine determina-
tion. Guidelines for response in the previously trea-
ted  patients  were  those  developed  by  the  NCI
sponsored  Working  Group.23 Complete  response
(CR) required the absence of symptoms and organo-
megaly,  and  a  normal  complete  blood  cell  count
(absolute neutrophil count >13 109/l and bone mar-
row with less than  30% of lymphocytes for at  least
2  months).  Residual  disease  was  evaluated  in  CR
patients by immunophenotyping of peripheral blood
and bone marrow. We have used a simultaneous dual
color  staining  flow  cytometry.  Blood  was  collected
in  vacuum tubes with EDTA as anticoagulant. Bone
marrow  cells  were  aspirated  from  the  dorsal  iliac
crest and immediately put into heparinized tubes.26
Flow cytometry analysis was performed by EPICS-XL
(Coulter,  Hialeah,  FL,  USA).  A  combination  of  iso-
thiocyanate  (FITC)  conjugated  monoclonal  antibo-
dies was used. Residual disease was determined by
the coexpression of CD5/CD19 and CD5/CD20 on B
lymphocytes  in  conjunction  with  monoclonality  of
surface  light-chain  expression  on  CD5  positive  B
cells. The  presence  of  more  than  10%  of  the  total
lymphocytic  population  coexpressing  CD19/CD5
and  CD20/CD5  with monotypic light  chain  expres-
sion  was  considered  as  monotypic  light  chain
expression.26
Serum sampling and cytokine determination
Venous blood samples were collected in pyrogen free
tubes, allowed to clot at – 4°C for 1 h and centrifuged
at 2000 g for 10min. The serum obtained was divided
into aliquots and stored at – 70°C until assayed for IL-
6,  OSM,  LIF,  sIL-6R  ang  gp130.  The  sera  were
randomly  coded  and  the  testing  was  carried  out
without the knowledge of the clinical status of the
subject or their related laboratory data. The cytokine
serum concentration  was  assayed  by  specific,  com-
mercially available, enzyme linked assay (ELISA) kits
(Quantikine, R&D Systems Inc, USA) in  accordance
with  the  manufacturer’s  instructions  and  analyzed
with an ELISA reader at 492 mm. The procedure has
been described in details elsewhere.27,29 The sensitiv-
ity of the assay for IL-6 was 0.7 pg/ml; for LIF 2.0 pg/
ml and for OSM 2.1 pg/ml. Serum for SIL-6R concen-
tration  measurement  was  diluted  40  times  and  its
level was measured between 7.8 and 500pg/ml. The
minimum  detectable  dose  of  gp130  was  less  than
0.05 ng/ml.
IL-6 type cytokines in B-CLL
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Table 2. Serum levels of IL-6, OSM, sIL-6R and sgp130 in untreated patients with CLL, patients treated with 2-CdA and normal
control group. Median and range in parentheses
Cytokines and receptors All
patients
(n = 63)
(a)
Untreated
patients
(n = 25)
(b)
Patients
treated
with 2-CdA
(n = 38)
(c)
Control
group
(n = 17)
(d)
Statistical
analysis
IL-6 (pg/ml) n1 = 62 n1 = 25 n1 = 37 n1 = 17 a&d P<0.02*
Median 2.3 2.2 2.25 6.3 b&d N.S.
Range 0.0–66.7 0.8–66.7 0–34.4 0.5–14.6 c&d P<0.02*
b&c P<0.02*
OSM (pg/ml) n1 = 37 n1 = 20 n1 = 14 n1 = 1 a&d P<0.002*
Median 0.45 1.8 0.0 0.0 b&d P<0.001*
Range 0.0–22.5 0–22.5 0–12.8 0–1.1 c&d N.S.
b&c N.S.
sIL-6R (ng/ml) n1 = 63 n1 = 25 n1 = 37 n1 = 17 a&d P<0.004*
Median 53.18 61.8 50.1 41.2 b&d P<0.001*
Range 33.8–101.67 33.8–101.67 34.7–103.8 23.7–64.5 c&d P = 0.04*
b&c P = 0.04*
sgp130 (pg/ml) n1 = 63 n1 = 25 n1 = 37 n1 = 17 a&d N.S.
Median 460 480 470 420 b&d N.S.
Range 310–970 310–730 330–970 310–710 c&d N.S.
b&c N.S.
*Statistically  significant  difference;  n =  number of  investigated  patients;  n1 =  number  of  individuals  with  detectable  cytokines;  N.S.,  non-
significant difference.Statistical analysis
The mean values were compared in Mann–Whitney U
test and Kruskal–Wallis test. Statistical analysis for the
frequency  of  detectable  cytokines  was  performed
using Chi-squared test. Zero values, indicating unde-
tectable levels, were included in all the analyses. The
linear correlations between serum interleukin levels,
as  compared  with  the  lymphocyte  number,  were
evaluated  using  the  Sperman  rank-sum  correlation
coefficient  and  linear  regression  with  the  least
squares  method.  The  comparison  and  correlation
were considered significant when P<0.05.
Results
The results of the measurement of IL-6, OSM, LIF , sIL-
6R  and  sgp130  in  untreated  patients  and  patients
treated  with  2-CdA  are  shown  in Table  2.  IL-6  was
measurable in 37/38 (97.4%) treated patients, in all 25
untreated patients and in all normal individuals. sIL-6R
and sgp130 were detectable in all the patients and in
all  the  healthy  controls.  In  contrast,  OSM  was
measurable  in  20/25  (80%)  of  the  untreated  CLL
patients, in 14/38 (37.8%) of the treated patients and
only in 1/17 (5.9%) of the healthy persons. Because
LIF was not detectable in any of the CLL patients, as
well as in any person from the control group, we did
not  carry  out  any  statistical  analysis  for  this
cytokine.
In our study the IL-6 serum level in  CLL patients
(median 2.3 pg/ml) was significantly lower than in the
healthy  controls  (median  6.3 pg/ml;  P<0.02).  The
lowest concentration of this cytokine has been found
in CR (median 1.4 pg/ml; P<0.002; Table 3). However,
the  level  of  IL-6  in  the  untreated  patients  was  not
significantly different  as compared to its concentra-
tion in the control group.
The serum OSM level was significantly higher in the
CLL  patients  (median  0.45 pg/ml),  when  compared
with  the  normal  individuals  (median  0.0 pg/ml;
P<0.002). Moreover, it was at its highest level in the
untreated  CLL  patients  (median  1.8 pg/ml). In  con-
trast,  there  was  no  significant  difference  between
OSM levels in the patients with CR and the control
group (P>0.05).
The serum concentration of sIL-6R was significantly
higher  in  the  untreated  (median  61.8 ng/ml)  and
treated (median 50.1ng/ml) CLL patients when com-
pared  to  normal  persons  (median  41.2 ng/ml;
P<0.001  and  P=0.04,  respectively).  There  was  no
difference  between  the  serum  sIL-6R  level  in  the
patients  with  CR  and  the  healthy  control  group
(P<0.05). Moreover, in patients who did not respond
to  2-CdA  treatment,  the  sIL-6R  concentration  was
higher than in the responding patients, and similar to
its level in the untreated group (P>0.05).
The serum concentration of sgp130 was similar in
the  untreated  (median  480 pg/ml)  and  treated
(median 470pg/ml) patients as well as in the healthy
persons (median 420 pg/ml). No correlation between
the level of these soluble receptor and the response to
treatment was found.
T. Robak et al.
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Table 3. Serum levels of IL-6, OSM, sIL-6R and sgp130 in patients with CLL according to treatment response. Median and range
in parentheses
Cytokines and receptors Untreated
patients
(n =  25)
(a)
Patients
with CR
(n = 7)
(b)
Patients
with PR
(n = 18)
(c)
Non-responded
patients
(n = 13)
(d)
Control
group
(n = 17)
(e)
Statistically
significant
comparisons
IL-6 (pg/ml) n1 = 25 n1 = 7 n1 = 17 n1 = 13 n1 = 17 a–e P = 0.05
Median 2.2 1.4 2.65 2.8 6.3 b&e P<0.02*
Range 0.8–66.7 1.0–2.5 0–24.5 0–34.4 0.5–14.6
OSM (pg/ml) n1 = 20 n1 = 2 n1 = 6 n1 = 6 n1 = 1 a–e P = 0.0001*
Median 1.8 0 0 0 0 a&b P<0.03*
Range 0–22.5 0–1.2 0–12.8 0–3.0 0–1.1 a&c P<0.004*
a&d P<0.004*
a&e P< 0.001*
sIL-R (ng/ml) n1 = 25 n1 = 7 n1 = 18 n1 = 13 n1 = 17 a–e P<0.001*
Median 61.8 37.5 50.6 74.2 41.2 a&b P<0.001*
Range 33.8–101.7 35.9–40.6 34.7–107.3 41.8–103.8 23.7–64.5 a&c P<0.05*
a&e P<0.001*
b&c P<0.005*
b&d P<0.001*
c&d P<0.05*
c&e P<0.05*
d&e P<0.001*
sgp130 (pg/ml) n1 = 25 n1 = 7 n1 = 18 n1 = 13 n1 = 17 a–e P<0.05*
Median 480 490 415 510 420
Range 310–730 330–550 350–970 340–740 310–710
*Statistically significant difference; n = number of investigated patients; n1 = number of individuals with detectable cytokines.Surface  immunofenotyping  by  flow  cytometry
using  the  dual  color  staining  technique  on  the
peripheral  blood  and  /or  bone  marrow  was  per-
formed in all seven patients with 2-CdA induced CR.
Residual  disease  was  demonstrated  in  three  out  of
these  patients.  The  serum  levels  of  investigated
cytokines and soluble receptors were similar  in the
patients with and without residual disease (data not
shown).
In the group of active CLL patients we have also
analyzed the relationship between the serum concen-
tration of evaluated cytokines, as well as the soluble
receptors  and  the  clinical  stage  according  to  Rai
(Table 4). The lowest IL-6 concentration was found in
the patients with Rai 1&2 (median 1.5 pg/ml) as well
as  those  with  Rai  0  (median  2.3 pg/ml);  and  the
highest  concentration  in  Rai  3&4  patients  (median
6.05 pg/ml).
IL-6 type cytokines in B-CLL
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Table 4. Serum levels of IL-6, OSM, sIL-6R and sgp130 in patients with CLL by Rai stage and in normal control group. Median
and range in parentheses.
Group
cytokines
All
patients
(n = 63)
(a)
CR
(n = 7)
(b)
Rai = 0
(n = 9)
(c)
Rai = 1&2
(n = 25)
(d)
Rai = 3&4
(n = 20)
(e)
Control
group
(n = 17)
(f)
Statistical
analysis for
means
Statistical
analysis for
frequency of
detectable
cytokines
IL-6 (pg/ml) n1 = 62 n1 = 7 n1 = 11 n1 = 27 n1 = 20 n1 = 17 b–f P<0.001*
Median 2.3 1.4 2.3 1.5 6.05 6.3 a&f P<0.02*
Range 0.0–66.7 1.0–2.5 0.5–16.1 0.0–45.4 0.4–66.7 0.5 –14.6 b&f P<0.04*
c&d P<0.003*
c&f P<0.002*
d&e P<0.005*
e&f P<0.002*
sIL-6R(ng/ml) n1 = 63 n1 = 7 n1 = 9 n1 = 27 n1 = 20 n1 = 17 b–f P<0.001*
Median 53.18 37.49 46.69 62.06 53.26 41.19 a&f P<0.004*
Range 33.8–107.34 35.97–40.63 36.42–107.34 33.80–101.67 34.74–103.85 23.73–67.92 b&d P<0.001*
b&e P<0.001*
c&e P<0.001*
c&f P<0.001*
d&e P<0.001*
d&f P<0.001*
e&f P<0.002*
OSM (pg/ml) n1 = 37 n1 = 2 n1 = 4 n1 = 20 n1 = 11 n1 = 1 b–f P<0.001* –
Median 0.45 0.0 0.0 1.2 0.15 0.0 a&f P<0.002* P<0.001*
Range 0.0–22.50 0.0–1.2 0.0–10.7 0.0–12.8 0.0–22.5 0.0–1.1 c&f P<0.001* N.S.
d&f P<0.03* P<0.001*
e&f N.S. P<0.01*
sgp130(pg/ml) n1 = 63 n1 = 7 n1 = 9 n1 = 27 n1 = 20 n1 = 17 b–f N.S.
Median 460 490 430 440 495 420 a&f N.S.
Range 310–970 330–550 350–970 310–740 340–730 310–710
*Statistically significant difference; N.S., non-significant difference.
Table 5. sIL-6R/IL-6 ratio and sgp130/IL-6 ratio in the patients with CLL according to treatment response. Median and range in
parentheses.
Cytokines and receptors Untreated
patients
(n = 25)
(a)
Patients
with CR
(n = 7)
(b)
Patients
with PR
(n = 18)
(c)
Non-
responded
patients
(n = 13)
(d)
Control
group
(n = 17)
(e)
Statistically
significant
comparisons
sIL-6R/IL-6 n1 = 25 n1 = 7 n1 = 17 n1 = 13 n1 = 17 a–e P<0.03*
Median 22 531 25 694 21 9534 26 510 8209 a&e P<0.02*
Range 630–76 556 14 619–37 492 1724–113 640 2974–107 390 4234–85 816 b&e P<0.002*
d&e P<0.007*
sgp130/IL-6 n1 = 25 n1 = 7 n1 = 17 n1 = 13 n1 = 17 b–e N.S.
Median 207 250 143 179 89 b–e P<0.003*
Range 8.8–600 179.0–540 15.9–1675 9.9–850 28.8–1160 d–e P<0.007*
*Statistically  significant  difference;  n = number of investigated  patients;  n1 =  number of individuals  with detectable  cytokines;  N.S., non-
significant difference.T. Robak et al.
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FIG. 1. Correlation between the serum levels of IL-6, OSM, sIL-6R and sgp130 with the number of lymphocytes in the peripheral
blood of CLL patients.IL-6 type cytokines in B-CLL
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.The OSM serum level was  higher in  the patients
with Rai 0 and with Rai 1&2, when compared to the
normal controls (P<0.001 and P<0.03, respectively).
Although the serum concentration of this cytokine in
the patients with Rai 3&4 was not significantly higher,
we observed that it was detectable more often in this
group, when compared with the controls.
However, the sIL-6R concentration was highest in
the  patients  with  advanced  Rai  stage  1&2  (median
62.06 ng/ml)  and  3&4  (median  53.26 ng/ml)  and
lowest in patients with Rai O (median 46.69 ng/ml).
No difference between the gp130 level and clinical
stage of the patients was observed.
The calculation of the sIL-6R to IL-6 ratio, as well as
sgp130  to  IL-6  ratio  in  the  CLL  patients  and  the
healthy  controls,  are  presented  in Table  5. The  sIL-
6R/IL-6 ratio was  significantly  higher in  the  treated
patients (median 23040.0) when compared to untrea-
ted (median 22530.6) CLL patients (P<0.0006). More-
over, it  was also higher in  both groups than  in  the
normal  individuals  (median  8209.7;  P<0.0006  and
P<0.02, respectively). The highest ratio was observed
in patients who did not respond to 2-CdA treatment
(median 26510.0).
We have also found a significantly higher sgp130/IL-
6  ratio  in  patients  treated  with$  2-CdA  (median
208.0), when compared with untreated CLL patients
(median 206.7; P<0.01).
The relationship between the serum concentration
of evaluated cytokines as well as the soluble receptors
and lymphocytes count are shown in Fig. 1. We have
only found a significant positive correlation between
the  levels  of  sIL-6R  and  lymphocytes  count  in  CLL
patients (=0.423; P<0.001). We have also analyzed the
relationship between serum levels of IL-6 with both
OSM  and  the  soluble  receptors  (Fig.  2). The  only
significant correlation was observed between IL-6 and
sIL-6 levels in CLL patients (r =0.244; P<0.005).
Discussion
The  role  of  cytokines  in  the  pathogenesis  and  the
clinical  course  and  the  monitoring  of  neoplasmatic
diseases has been intensively investigated for the last
several  years.  It  seems  that  the  most  important
cytokines, which play a key role in the pathogenesis
of  CLL, are  IL-2,  IL-4 and TNFa .29 –32 The results  of
some studies also indicate that IL-6 may play a role in
the  pathomechanism  of  CLL.9,12 Other  cytokines
belonging  to  the  IL-6  family  have  not  been  yet
investigated in CLL. In our study the concentration of
three  cytokines  belonging  to  IL-6  family  has  been
measured in the serum of 63 patients with B-CLL who
had been previously untreated or who had received
2-CdA  as  a  first  line  treatment,  including  seven
patients who achieved a CR, and in a control group of
17 healthy volunteers. IL-6 was measurable in all but
one  of  the  B-CLL  patients  and  in  all  the  healthy
volunteers. OSM was detectable in 80% of untreated
and in 37.8% of 2-CdA treated B-CLL patients, but was
measurable  only  in  5.9%  of  the  controls.  LIF  was
undetectable in  all B-CLL patients, as well as in the
control group.
The  mean  concentration  of  IL-6  in  the  serum  of
untreated  patients  with  CLL  was  not  significantly
different,  when  compared  to  healthy  controls.  It  is
worth stressing that IL-6 concentration was lower in
the  treated  CLL  patients  than  in  the  untreated
subgroup (P<0.02). We have also shown that IL-6 was
at its lowest concentration in patients in a CR upon
2-CdA  (median  1.4 pg/ml), median  in  a PR  (median
2.65 pg/ml), and at its highest level in non-responding
patients  (median  2.8 pg/ml).  The  results  of  other
studies on IL-6 in CLL have reported earlier generally
agreed  with  our  observations.33,34 Callea  et  al.34
showed  that  the  serum  concentration  of  IL-6  is
statistically  higher  in  patients  with  advanced  or
progressive  stage  of  disease  in  comparison  with
smouldering B-CLL. Nevertheless, there was no statis-
tically  significant  difference  in  IL-6  concentration
between B-CLL patients and healthy controls. How-
ever,  Auguilar-Santelises  et  al.33 showed  that  in
patients  with  monoclonal  lymphocytosis  of  unde-
termined significance (MLUS) IL-6 concentration was
twice  as  high  as  in  healthy  controls;  but  in  B-CLL
patients  with  stable  as  well  as  with  in  progressive
disease the concentration of this cytokine was similar
to the control group.
The influence of treatment  of cytokines levels in
CLL  has  not  been,  as  yet,  intensively  studied.  Our
observations indicate that IL-6 level was higher in the
patients  with  more  advanced  Rai  stages  and  at  its
lowest in patients with 2-CdA induced remission. It is
generally known that 2-CdA exerts a strong lymphocy-
tolytic effect against leukemic B lymphocytes, which
is  not  selective.  This  agent  causes  a  long-lasting
suppression of T CD4+ lymphocytes and monocytes
which produce IL-6, in a similar way to leukemic B
lymphocytes.35–37 It is supposed that the decrease of
this cytokine in the serum of CLL patients upon 2-CdA
treatment, particularly in those achieving a CR, even
below normal limits, may be explained by the 2-CdA-
induced cytolytic effect on various cells producing IL-
6,  including  normal  and  leukemic  lymphocytes.
Dysregulation  of  the  secretion  of  IL-6  and  other
cytokines  was  reported  by  Jewell  et  al.38 in  B-CLL
patients treated with INF-a .
Until  now,  LIF  and  OSM  have  not  been  widely
investigated  in  patients  with  CLL.  Loregot  et  al.39
measured LIF concentration in the serum of patients
with various lymphoid malignancies and showed that
its  concentration  was  increased  in  Hodgkin’s  lym-
phoma (HL) and in non-Hodgkin’s lymphoma (NHL),
but in CLL and in healthy controls it remained low. In
our study LIF concentration, measured with commer-
cially available kits utilizing the ELISA  method, was
T. Robak et al.
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It  should  be  emphasized  that  similar  results  were
earlier  obtained  in  multiple  myeloma,28 systemic
lupus erythematodes27 and rheumatoid arthritis.22 In
contrast, OSM was detectable in a majority (80%) of
untreated  patients  with  CLL  and  in  only  37.8%  of
2-CdA-treated patients, as well as in only one (5.9%)
healthy control. Moreover, the concentration of this
cytokine was significantly higher in untreated patients
(median  1.8 pg/ml)  than  in  2-CdA  treated  patients
(median  0.0pg/ml,  P<0.05),  or  than  in  healthy
subjects  (median  0.0;  P<0.001). The  lowest  values
were noted in patients achieving a CR. Similar results
were reported earlier in multiple myeloma, where the
OSM  concentration  was  statistically  higher  in  pro-
gressive  disease  than  in  the  control  group.28 These
observations  are  concomitant  with  those  made  by
Koskela et al.40 who detected OSM in 20% of patients
with  multiple  myeloma.  Our  results  indicate  that
OSM,  like  IL-6,  may  have  a  significance  in  the
pathogenesis  of  CLL  and  may  be  useful  for  the
monitoring of the clinical course and effectiveness of
therapy in lymphoid malignancies.
Soluble  IL-6  receptors  (sIL-6R  and  sgp  130)  are
detectable  in  the  serum  and  other  body  fluids  in
healthy  controls  and  in  various  pathological  condi-
tions.17,20,22 sIL-6R has the agonist properties because
it is able to bind IL-6 with an affinity almost like that
of membrane IL-6R. Moreover, Il-6/sIL-6R complex is
able to bind and activate the gp130 transducer chain.
In our study the highest sIL-6R level was observed in
the serum of untreated CLL patients, and the lowest
values  were  noted  in  healthy  controls  and  in  CLL
patients who entered a CR (Table 3). Lavabre-Bertrand
et  al.20 also  reported  a  significantly  higher  sIL-6R
concentration in the serum of patients suffering from
various lymphoid malignancies, including CLL. They
showed that the sIL-6R concentration was higher in
more  advanced  stages  of  disease  and  suggested  its
correlation  with tumor cell mass. However, in  con-
trast  to  our  observations,  they  did  not  show  the
influence  of  therapy  on  the  concentration  of  this
soluble receptor. This discrepancy may be explained
by the fact that their patients were treated with the
chlorambucil or CHOP schedule and did not receive
purine  analogs;  which  may  exert  a  more  selective
effect  on  the  lymphoreticular  system,  resulting  in
more  complex  relationship  between  the  cytokines
and their soluble receptors. It is also known that sIL-
6R may be generated by the shedding of membrane
IL-6R, as well as by the translation of an alternatively
spliced RNA.41,42 The significant positive correlation
between the sIL-6R levels and the number of lympho-
cytes  confirmes  the  observation  made  by  Lavabre-
Bertrand  et  al.20 that  leukemic  B  lymphocytes  are
released sIL-6R mainly via shedding.
gp130 plays a key role in signal transmission for all
the cytokines of IL-6 family (Peters et al.18). gp130
mRNA  is  ubiquitously  expressed  in  almost  all  the
examined  organs,  including  the  spleen,  liver,  lung,
brain and heart.43 In  contrast to sIL-6R, the soluble
form of gp130  shows antagonist properties. Plasma
sgp130 has been shown to bind circulating IL-6/sIL-6R
complex and in this way to prevent cells expressing
membrane  gp130  from  being  activated.17 To  our
knowledge  sgp  130  concentration  in  the  serum  of
patients  with  lymphoid  neoplasmas  has  not  been
investigated as yet. The concentration of sgp 130 was
similar in the control group and in the CLL patients, as
well as in untreated and 2-CdA treated patients. The
results of our studies suggest that dysregulation of this
protective mechanism may be involved in the patho-
genesis of CLL. We can  also state that  this receptor
plays a minor role as an indicator of the tumor mass or
a marker of the disease advancement and therapeutic
efficacy than sIL-6R, because its concentrations in the
serum of CLL patients before and after treatment and
in  healthy  controls  do  not  differ  statistically.  The
differences  in  observations  concerning  these  two
soluble  receptors  are  difficult  to  interpret  and  the
quantitative analysis of the density of these receptors
on  the  membrane  of  leukemic  cells  may  provide
important information for the better understanding of
the  mechanism  of  their  proteolytic  cleavage  in  the
soluble form.
In conclusion, we have showed that serum concen-
tration of IL-6 is decreased, but OSM and sIL-6R are
increased  in  B-CLL  patients  in  comparison  with
healthy controls and correlates with the tumor mass
and  clinical  stage  of  disease.  Moreover,  in  patients
achieving  a  CR  upon  2-CdA  the  level  of  these
cytokines is similar to that in the control group, and in
case of IL-6 it is even lower. The serum concentration
of sgp130 does not differ significantly between CLL
patients and healthy subjects, so its measurement has
no practical  value  in  the  monitoring of  the  disease
activity and the efficacy of therapy.
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